LB 862 – NebraskaStatus: Inactive / Dead
Year Introduced: 2018
PRESCRIPTION DRUG COST TRANSPARENCY ACT: This Act is intended to promote transparency of the cost of manufacturing prescription pharmaceuticals. The Act would require that a manufacturer of a prescription drug notify certain parties such as insurance companies and health providers in the event that a cost increase on prescription drugs with a wholesale cost of forty dollars for one course of therapy is to increase more than sixteen percent in a prescribed period of time. LB 862 also assigns reporting requirements and publishing of such cost increases by the Department of Administrative Services.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.